Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 Data

Rezafungin (CD101) is a novel echinocandin antifungal agent currently in clinical development for the treatment of candidemia and invasive candidiasis. Rezafungin has potent in vitro activity against Candida albicans and Candida glabrata, including azole- and echinocandin-resistant isolates. The obj...

Descripción completa

Detalles Bibliográficos
Autores principales: Lakota, Elizabeth A., Ong, Voon, Flanagan, Shawn, Rubino, Christopher M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2018
Materias:
Clinical Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5971566/
https://www.ncbi.nlm.nih.gov/pubmed/29555631
http://dx.doi.org/10.1128/AAC.02603-17

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5971566/
https://www.ncbi.nlm.nih.gov/pubmed/29555631
http://dx.doi.org/10.1128/AAC.02603-17

Ejemplares similares